Table 3:
Summary of adverse events (AEs) following intravenous administration of AB023
| AB023 | Pooled Placebo | ||
|---|---|---|---|
| Treatment | Total | ||
| Trial Participants, n | 21 | 16 | 5 |
| Trial Participants Dosed, n (%) | 21 | 16 | 5 |
| Trial Participants with AEs, n (%) | 10 (48) | 7 (44) | 3 (60) |
| Total AEs, n | 20 | 15 | 5 |
| Mild | 17 | 12 | 5 |
| Moderate | 3 | 3 | 0 |
| Severe | 0 | 0 | 0 |
| Relationship to Study Drug, n | |||
| Unrelated | 5 | 3 | 2 |
| Unlikely | 10 | 7 | 3 |
| Possibly | 5 | 5 | 0 |
| Probably | 0 | 0 | 0 |
| Likely | 0 | 0 | 0 |
| Most Common AE, n | |||
| Productive cough | 2 | 2 | 0 |
| Possibly Treatment Related AEs, n | |||
| Diastolic blood pressure increased | 1 | 1 | 0 |
| Injection site ecchymosis | 1 | 1 | 0 |
| Injection site pain | 2 | 2 | 0 |
| Pruritus, generalized | 1 | 1 | 0 |